Sanofi Stock: Shares Drop Nearly 5% Following Paul Hudson's Departure
Sanofi's stock experienced a sharp decline this Thursday morning, dropping 4.71% to 78.67 euros amid changes at the helm of the pharmaceutical group. The board of directors announced the non-renewal of CEO Paul Hudson's term and the appointment of Belén Garijo as his successor. This decline is part of a marked downward trajectory, with the stock having lost more than 24% over the past year.
Corporate Developments at Sanofi
Sanofi is undergoing a period rich in corporate events. The board of directors decided to appoint Belén Garijo as the new CEO, replacing Paul Hudson whose term will not be renewed. The former leader of Merck KGaA will officially take over after the general meeting scheduled for April 29, 2026. This change in governance comes as the group has been showing significant stock market underperformance over the last twelve months. In parallel, the company has completed the acquisition of Dynavax Technologies, whose shares were removed from NASDAQ on February 10. This acquisition allows Sanofi to add the adult hepatitis B vaccine HEPLISAV-B and a shingles vaccine candidate currently in phase 1/2 clinical trials to its portfolio. The next financial appointment is set for April 23, with the publication of the first quarter 2026 results, which will be the first numerical test under the new governance.
Technical Analysis of Today's Session
Technically, today's session marks a significant break. The price of 78.67 euros falls well below the 50-day moving average, located at 81.86 euros, a signal generally interpreted as a weakening of the medium-term bullish momentum. This downward crossing is all the more significant as the stock is now well below its 200-day moving average (84.52 euros), confirming a southward-oriented fundamental trend. The nearest technical support is at 77.08 euros, a threshold towards which the stock could converge if selling pressure persists. The RSI, at 65, does not indicate an oversold situation and leaves room for further decline before reaching levels considered excessive. Over three months, the performance stands at -11.66%, while monthly volatility remains contained at 6.96, indicating a regular correction movement rather than a sharp drop.
